| Literature DB >> 34325730 |
Rossella Panarese1, Roberta Iatta1, Jairo Alfonso Mendoza-Roldan1, Andrea Zatelli1, Frederic Beugnet2, Domenico Otranto3,4.
Abstract
BACKGROUND: Leishmania infantum and Dirofilaria immitis are among the most important canine vector-borne pathogens (CVBPs) of zoonotic concern in Europe. In endemic areas for both of these CVBPs, the use of systemic ectoparasiticides, such as afoxolaner (NexGard®; Boehringer Ingelheim Animal Health), may have the potential for controlling these infections. The aim of this study was to assess, for the first time, the insecticidal efficacy of NexGard® in decreasing the transmission of D. immitis and L. infantum to sheltered dogs living in a hyperendemic area, compared to the year before treatment, as well as its impact on the abundance of mosquito and sand fly populations.Entities:
Keywords: Afoxolaner; Chemoprophylaxis; Dirofilariosis; Incidence; Insecticide; Leishmaniosis; NexGard®
Mesh:
Substances:
Year: 2021 PMID: 34325730 PMCID: PMC8323259 DOI: 10.1186/s13071-021-04883-3
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Number of dogs positive for Dirofilaria immitis and Leishmania infantum infections at three time points in 2020, prevalence of both infections in 2020 and number of new cases in March 2021
| Time pointsa | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| IFAT-positive, | IFAT-negative, | Prevalence, | 95% CI | Positive, | Negative, | Prevalence, | 95% CI | ||
| Knott’s test | SNAP test | ||||||||
| T0 (March 2020) | 76 | 103 (G1-L) | 76/179 (42.5) | 35.4–49.8 | 68 | 115 | 63 (G1-D) | 116d/179 (64.8) | 57.6–71.4 |
| T1 (June 2020) | 86 | 83 (retained from 93b,c) | 86/179 (48) | 40.8–55.3 | 19 | 23 | 40 | 139/179 (77.7) | 71.0–83.1 |
| T2 (October 2020) | nt | nt | na | na | 5 | 9 | 27 (retained from 30 b,c) | 149d/179 (83.2) | 77.1–88.0 |
| T3 (March 2021) or seasonal infection rate (incidence) | 3 | 80 | 3/83 (3.6) | 1.0–10.1 | 1 | 1 | 26 | 1/27 (3.7) | 0.2–18.1 |
CI Confidence interval, IFAT immunofluorescence antibody test,nt not tested, na not applicable
aT0, enrollment (day 0 ); T1, T0 + 90 days); T2, T0 + 210 days; T0 + 330 days
bOne and five dogs negative for D. immitis and L. infantum, respectively, were adopted after T2 and lost to further follow-up; therefore, they were not included in the evaluation of the post-treatment incidence in March 2021
cThree and five dogs negative for D. immitis and L. infantum, respectively, were included later in the study (T1 and T2) and their T3 (day + 330) was in April/June 2021; these dogs were therefore not included in the evaluation of the post-treatment incidence in March 2021
dThe number of positive dogs increased by 1 based on quantitative PCR
Number of female mosquito specimens and positive pools molecularly tested for Dirofilaria immitis along with the average number of mosquitoes per pool, minimal infection rate and percentage of estimated rate of infection
| Mosquito species | No. of mosquitoes | No. of females | No. of pools positive/tested | Mean no. of mosquitoes per pool | MIR (/1000) | ERI (%) |
|---|---|---|---|---|---|---|
| 66 | 66 | 1/14 | 4.7 | 15.2 | 1.6 | |
| 97 | 41 | 0/14 | 2.9 | – | – | |
| 28 | 16 | 0/10 | 1.6 | – | – | |
| 11 | 10 | 0/3 | 3.3 | – | – | |
| 11 | 9 | 0/4 | 2.25 | – | – | |
| 2 | 2 | 0/2 | 1 | – | – | |
| 4 | 2 | 0/3 | 1 | – | – | |
| Total | 219 | 146 | 1/50 | 2.4 | 6.8 | 0.8 |
ERI Estimated rate of infection, MIR minimal infection rate
aDamaged mosquito specimens morphologically identified at the genus level only
Number of female mosquito specimens collected in 2019 in the dog shelter and positive pools molecularly tested for Dirofilaria immitis along with the average number of mosquitoes per pool, MIR and percentage of ERI
| Mosquito species | No. of mosquitoes | No. of females | No. of pools positive/tested | Mean no. of mosquitoes per pool | MIR (/1000) | ERI (%) |
|---|---|---|---|---|---|---|
| 131 | 129 | 3/15 | 8.6 | 23.3 | 3 | |
| 43 | 37 | 0/11 | 3.4 | – | – | |
| 45 | 36 | 1/7 | 5.2 | 27.8 | 3 | |
| 1 | 1 | 0/1 | 1 | – | – | |
| 1 | 1 | 0/1 | 1 | – | – | |
| 2 | 2 | 0/1 | 2 | – | – | |
| 1 | 1 | 0/1 | 1 | – | – | |
| 1 | 1 | 0/1 | 1 | – | – | |
| Total | 225 | 208 | 4/38 | 5.5 | 19.2 | 2 |